Association between evolocumab use and slow progression of aortic valve stenosis
Heart and Vessels · 2024
DOI: 10.1007/s00380-024-02386-6 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Heart and Vessels, 2024. Verfasst von Kengo Terasaka und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Aortic Valve Stenosis, Disease Progression. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
No medications have been reported to inhibit the progression of aortic valve stenosis (AS). The present study aimed to investigate whether evolocumab use is related to the slow progression of AS evaluated by serial echocardiography. This was a retrospective observational study from 2017 to 2022 at Yokohama City University Medical Center. Patients aged ≥ 18 with moderate AS were included. Exclusion criteria were (1) mild AS; (2) severe AS defined by maximum aortic valve (AV) velocity ≥ 4.0 m/s; and/or (3) no data of annual follow-up echocardiography. The primary endpoint was the association between evolocumab use and annual changes in the maximum AV-velocity or peak AV-pressure gradient (PG). A total of 57 patients were enrolled: 9 patients treated with evolocumab (evolocumab group), and the other 48 patients assigned to a control group. During a median follow-up of 33 months, the cumulative incidence of AS events (a composite of all-cause death, AV intervention, or unplanned hospitalization for heart failure) was 11% in the evolocumab group and 58% in the control group (P = 0.012). Annual change of maximum AV-velocity or peak AV-PG from the baseline to the next year was 0.02 (- 0.18 to 0.22) m/s per year or 0.60 (- 4.20 to 6.44) mmHg per year in the evolocumab group, whereas it was 0.29 (0.04-0.59) m/s per year or 7.61 (1.46-16.48) mmHg per year in the control group (both P < 0.05). Evolocumab use was associated with slow progression of AS and a low incidence of AS events in patients with moderate AS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan.
- Advanced Critical Care and Emergency Center, Yokohama City University Medical Center, Yokohama, Japan.
- Division of Cardiology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan. gocchi3@hotmail.com.
- Department of Laboratory Medicine and Clinical Investigation, Yokohama City University Medical Center, Yokohama, Japan.
- Department of Cardiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Zitieren
APA
Terasaka, K., Gohbara, M., Abe, T., Yoshii, T., Hanajima, Y., Kirigaya, J., Horii, M., Kikuchi, S., Nakahashi, H., Matsushita, K., Minamimoto, Y., Okada, K., Matsuzawa, Y., Iwahashi, N., Kosuge, M., Sugano, T., Ebina, T., & Hibi, K. (2024). Association between evolocumab use and slow progression of aortic valve stenosis. Heart and Vessels. https://doi.org/10.1007/s00380-024-02386-6
Vancouver
Terasaka K, Gohbara M, Abe T, Yoshii T, Hanajima Y, Kirigaya J, et al. Association between evolocumab use and slow progression of aortic valve stenosis. Heart and Vessels. 2024. doi:10.1007/s00380-024-02386-6
BibTeX
@article{Terasaka2024,
author = {Terasaka, Kengo and Gohbara, Masaomi and Abe, Takeru and Yoshii, Tomohiro and Hanajima, Yohei and Kirigaya, Jin and Horii, Mutsuo and Kikuchi, Shinnosuke and Nakahashi, Hidefumi and Matsushita, Kensuke and Minamimoto, Yugo and Okada, Kozo and Matsuzawa, Yasushi and Iwahashi, Noriaki and Kosuge, Masami and Sugano, Teruyasu and Ebina, Toshiaki and Hibi, Kiyoshi},
title = {Association between evolocumab use and slow progression of aortic valve stenosis},
journal = {Heart and Vessels},
year = {2024},
doi = {10.1007/s00380-024-02386-6}
}
EUVIMED